[Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Imatinib mesylate (imatinib) has shown significant effects in patients with chronic myelogenous leukemia. However, hematological toxicity often occurs and requires dosage reduction or discontinuation of imatinib treatment. A patient with chronic myelogenous leukemia in the blastic crisis received granulocyte-colony stimulating factor (G-CSF) simultaneously with imatinib. The patient was continuously treated with imatinib and G-CSF and achieved remission without any severe infection or neutropenia. There are a few reports on the efficacy of combined therapy with G-CSF and imatinib; however, the results in our case are rare suggesting that the use of G-CSF is effective for preventing severe infection. G-CSF enables continuous treatment with high-dose imatinib.
Morita
Rena
R
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine.
Hashino
Satoshi
S
Sogabe
Susumu
S
Dazai
Masayoshi
M
Onozawa
Masahiro
M
Izumiyama
Koh
K
Kondo
Takeshi
T
Ota
Syuichi
S
Kobayashi
Sumiko
S
Imamura
Masahiro
M
Asaka
Masahiro
M
D001424:Bacterial Infections / Q000517:prevention & control; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000517:prevention & control; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate